Form 8-K - Current report:
SEC Accession No. 0001140361-24-049072
Filing Date
2024-12-12
Accepted
2024-12-12 06:01:00
Documents
14
Period of Report
2024-12-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20039810x1_8k.htm   iXBRL 8-K 34072
2 EXHIBIT 2.1 ny20039810x1_ex2-1.htm EX-2.1 24767
  Complete submission text file 0001140361-24-049072.txt   202157

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20241211.xsd EX-101.SCH 3980
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20241211_lab.xml EX-101.LAB 21967
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20241211_pre.xml EX-101.PRE 16043
16 EXTRACTED XBRL INSTANCE DOCUMENT ny20039810x1_8k_htm.xml XML 4227
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 241543110
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)